Statistical analysis
We pooled risk ratios (RRs) with
95% confidence interval (CI) to determine the treatment effect of
Roxadustat on cardiac and renal disorders. All statistical analyses were
performed using the Stata MP Software (version 14). In the statistical
analysis of the effect of Roxadustat on cardiac and renal disorders, P
< 0.05 was deemed as a significant statistical difference.
Heterogeneity between trials was evaluated by employing Cochrane’s Q
test and reported as I-squared (I2). Heterogeneity was
categorized as low (I2 ≤ 40%), moderate
(I2 ≤ 70%) or high (I2 > 70%).
I2 ≤ 40% and p < 0.1 indicated that there
was a lack of homogeneity among the trials, and the fixed-effects model
was employed in the result analysis; otherwise, a random-effects model
was used. The source of heterogeneity was explored by the following
methods: (A) through sensitivity analysis, each trial was eliminated one
by one to identify the trial that caused the heterogeneity. (B) subgroup
analysis was conducted based on gender, age, country, and follow-up
duration